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Reduction of low-density lipoprotein receptor-
related protein (LRP1) in hippocampal neurons
does not proportionately reduce, or otherwise
alter, amyloid deposition in APPswe/PS1dE9
transgenic mice
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Abstract
Introduction: The low-density lipoprotein receptor-related protein (LRP1) and its family members have been
implicated in the pathogenesis of Alzheimer’s disease. Multiple susceptibility factors converge to metabolic
pathways that involve LRP1, including modulation of the processing of amyloid precursor protein (APP) and the
clearance of Ab peptide.
Methods: We used the Cre-lox system to lower LRP1 levels in hippocampal neurons of mice that develop
Alzheimer-type amyloid by crosses between mice that express Cre recombinase under the transcriptional control of
the GFAP promoter, mice that harbor loxp sites in the LRP1 gene, and the APPswe/PS1dE9 transgenic model. We
compared amyloid plaque numbers in APPswe/PS1dE9 mice lacking LRP1 expression in hippocampus (n = 13) to
mice with normal levels of LRP1 (n = 12). Student t-test was used to test whether there were significant
differences in plaque numbers and amyloid levels between the groups. A regression model was used to fit two
regression lines for these groups, and to compare the rates of Ab accumulation.
Results: Immunohistochemical analyses demonstrated efficient elimination of LRP1 expression in the CA fields and
dentate gyrus of the hippocampus. Within hippocampus, we observed no effect on the severity of amyloid
deposition, the rate of Ab40/42 accumulation, or the architecture of amyloid plaques when LRP1 levels were
reduced.
Conclusions: Expression of LRP1 by neurons in proximity to senile amyloid plaques does not appear to play a
major role in modulating the formation of these proximal deposits or in the appearance of the associated neuritic
pathology.
Introduction
Amyloid deposition is a key pathological event in Alz-
heimer’s disease. A large body of evidence suggests that
low density lipoprotein (LDL) receptor related protein
(LRP1), may be a key mediator of amyloid deposition.
As a member of the LDL receptor family, LRP1 is a
large, multifunctional, endocytic receptor that is highly
expressed in neurons (reviewed by Andersen [1]), acti-
vated astrocytes [2-4], and microglia [5]. Direct binding
of LRP1 to the amyloid precursor protein (APP) has
been shown to affect endoproteolytic processing of APP
to increase the production of Ab42 peptides [6], which
are the major constituent of amyloid deposits [7]. LRP1
can promote Ab production by altering the processing
of APP through interactions via the Kunitz protease
inhibitor (KPI) domain (isoforms APP751 or APP770)
[6]. Although the non-KPI-APP isoform can weakly
bind to LRP1 through cytoplasmic adaptor proteins,
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such as FE65 [8], APP695 processing may not be influ-
enced as significantly by LRP1. Additionally, LRP1 has
also been reported to mediate export of Ab across the
blood-brain barrier (reviewed by [9]); LRP1 in endothe-
lial cells may bind directly to Ab1-40 and export it
across the blood-brain barrier [10]. Consistent with this
notion, reducing LRP1 levels by antisense treatment
reduces blood-brain barrier clearance of Ab42 [11].
Polymorphisms in the LRP1 gene have been associated
with increased risk for Alzheimer’s disease [12] and
LRP1 levels are significantly reduced in AD patients
[13]. More recently, Sehgal and colleagues reported that
an extract of Withania somnifera induces a rapid clear-
ance of amyloid pathology with a co-incident induction
of LRP1 expression in liver [14]. Other proteins impli-
cated in amyloidogenesis have been identified as inter-
acting with LRP1 [15], such as apolipoprotien E (ApoE)
and a2-macroglobulin. Both of these proteins are
ligands of LRP1 and have been reported to mediate the
clearance of Ab [13,16-19]. Moreover, ApoE, which is a
major ligand for LRP1, modulates the distribution and
character of amyloid deposition [20]. Collectively, these
data suggest that LRP1 could be a crucial factor in Alz-
heimer’s disease and the receptor characteristics of
LRP1 make this protein a potential “drugable” target
where influencing the binding of LRP1 to any of its
ligands could be a useful therapeutic.
To date, there have been few studies that examine the
role of LRP1 in vivo using animal models by genetic
manipulation of LRP1 expression. Constitutive inactiva-
tion of LRP1 is lethal [21]. We [22] and others [23] have
used mice with targeted deletion of LRP1 receptor asso-
ciated protein (RAP), which regulates LRP1 maturation,
as a means to reduce LRP1 levels in mouse models of
Alzheimer’s disease. One group has reported that homo-
zygous deletion of RAP, which lowers LRP1 levels by
75% [24], results in increased Ab deposition in PDAPP
mice [23]. Similarly, we observed that heterozygous
deletion of RAP also increased amyloid deposition, in
the APPswe/PS1dE9 model; however, in our case LRP1
levels were not significantly lowered [22]. Expression of
an LRP1 mini-receptor at approximately 3.7-fold over
endogenous LRP1 levels in the PDAPP transgenic model
was reported to have no effect on amyloid burden [25].
Collectively, these studies illustrate the inconsistent in
vivo findings regarding LRP1 and amyloidogenesis in
transgenic mice that over-express mutant APP (with or
without co-expression of mutant presenilin).
To further probe the role of LRP1 in amyloidogenesis,
we used Cre/Lox technology to conditionally reduce
LRP1 expression in the brains of mice that co-express
mutant APP (APPswe) and mutant presenilin 1
(PS1dE9). For these studies we used mice that express
Cre under the control of the glial fibrillary acidic protein
(GFAP) [26]. In previous studies with these animals,
others have demonstrated Cre mediated recombination
in both neurons and glial throughout the brain [27]. In
our hands, GFAP-mediated expression of Cre produced
incomplete recombination, such that the levels of LRP1
in total brain were reduced approximately 50%. How-
ever, we determined that LRP1 immunostaining in CA
and granule neurons of the hippocampus was virtually
eliminated. Within the hippocampus, we observed no
obvious change in the level of neuritic pathology or
amyloid burden by loss of LRP1.
Materials and methods
Animals
Mice with targeted Lox P sites introduced into intronic
and promoter regions of the LRP1 gene were obtained
from Joachim Herz [28,29], called LRP1 lox/lox. Trans-
genic mice expressing GFAP-Cre were obtained from
Jackson Laboratories (Bar Harbor, ME, USA; Strain:
FVB-Tg(GFAP-cre)25Mes/J; Stock Number: 004600)
[26]. These animals were back-crossed to C57BL/6J
mice for at least four generations to reduce the FVB
strain contribution before breeding to LRP1 lox/lox
mice. LRP1 lox/lox mice were in parallel bred to
APPswe/PS1dE9 (line 85) mice [30] (both with C57BL/
6J background) to produce mice homozygous for the
LRP1 loxp locus. To generate triple transgenic mice, we
mated mice transgenic for GFAP-Cre and homozygous
for LRP1 loxp to mice transgenic for APPswe/PS1dE9
and homozygous for LPR loxp. FVB/NJ male and female
mice were purchased from Jackson Laboratories (stock
number: 001800) to produce foster mothers. Eventually,
animals with the genotypes of APPswe/PS1dE9(+)/LRP1
lox/lox with/without the GFAP-Cre gene were used for
the study. All of the mice were housed in standard SPF
cages for 9 to 18 months before harvesting. All proce-
dures involving animal handling and processing were
approved by the University of Florida Institutional Ani-
mal Care and Use Committee and in compliance with
the National Institutes of Health guidelines.
Western blot analysis
Levels of LRP1 were assessed by Western blot, using
standard methods we have previously described [31].
Aliquots of the PBS brain homogenates (100 μl) from
14- to 15-month-old mice were mixed with 10 μl of
10% SDS, centrifuged at the top speed (approximately
10,000 xg) in a bench top microfuge for 10 minutes,
and then 30 μl of the supernatant was mixed with 10 μl
4x Laemmli buffer and boiled for 5 minutes. An amount
of sample equal to 50 μg total protein (by BCA assay)
were loaded per lane for SDS-PAGE and transferred to
nitrocellulose membranes. Blots were incubated with
rabbit polyclonal antibody 377 aLRP1 (1:1,000) and
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then reprobed with the m/h SOD1 antibody (1:3,000) to
gauge protein loading [32]. The ECL signal was captured
and quantified using the LAS-3000 imaging system
(FUJIFILM Life Science, Tokyo, Japan).
Tissue preparation for histology
Mice were deeply anesthetized by injection anesthetic
(3% body weight of 1.2% Tribromoethanol (Avertin
Sigma, St. Louis, MO, USA) before transcardial perfu-
sion with cold phosphate buffered saline (PBS, pH7.4).
The brains were then removed and cut sagittally down
the midline; one hemi-brain was frozen on dry ice for
biochemistry assay, the other hemi-brain was immersion
fixed in 4% paraformaldehyde in PBS. After 48 hours in
fixation at 4°C, brains were transferred to PBS, and then
30% sucrose in PBS for several days before cryostat sec-
tioning at 30 μm thickness. From the first complete sec-
tion closest to mid-line, 10 sections per group were
stored in each well of 24-well-plates and the entire
hemi-brain was sectioned. Sections were kept in anti-
freeze solution (100 mM sodium acetate, 250 mM poly-
vinyl pyrrolidone, 40% ethylene glycol, pH6.5) at -20°C
until staining.
Immunostaining
Immunostaining of 30 μm free floating sections was per-
formed according to a standard protocol. Sections were
washed in PBS to remove the anti-freeze solution, and
then blocked in PBS containing 5% normal goat serum
with 0.1% Triton X-100 before incubating with antibo-
dies against LRP1 (rabbit polyclonal 377 aLRP1
(1:1,000)), glial fibrillary acidic protein (GFAP) (mouse
monoclonal, 1:1,000, Millipore, Billerica, MA, USA),
neuronal antigen NeuN (mouse monoclonal, 1:1000,
Millipore) or 6E10 (mouse monoclonal, 1:1,000, Cov-
ance, Princeton, NJ, USA). Secondary antibodies of goat
anti-rabbit and goat anti-mouse, conjugated with Alexa
594 or Alexa 488 (Invitrogen, Carlsbad, CA, USA) were
used to visualize primary antibody binding. After wash-
ing to remove unbound secondary antibody, the sections
were then mounted on microscope slides and dried in
air. A quick dip in 0.1% Sudan Black B solution (in 70%
ethanol) for 5 to 10 minutes was used to block the
auto-fluorescence of lipofuscin then the slides were
washed in 70% ethanol, then water, dried and covered
by ProLong Gold antifade reagent with Dapi (Invitro-
gen). An Olympus DSU-IX81 Spinning Disc Confocal
microscope (Tokyo, Japan) was used to capture the
images.
Thioflavin S staining and silver staining of amyloid
plaques
One section from each well (see above Tissue prepara-
tion for histology) was randomly selected for Thioflavin
S staining according to the Guntern standard protocol
[33] with small modification [34]. Fluorescent photos
were taken using 5x objectives by a Canon digital cam-
era (Tokyo, Japan). Silver impregnation staining was
performed on the same 30 μm floating sections by mod-
ified Hirano’s method [35,36]. Briefly, sections were
washed and mounted on slides to dry as those for Thio-
flavin S staining, and then the steps described for silver
impregnation methods of paraffin slides were followed
[36].
Amyloid plaque quantification
Four sections per animal (from 300 to 1,500 μm lateral
to midline) stained with Thioflavin S were used to quan-
tify the amyloid plaque levels. The images of the hippo-
campus were outlined and the numbers of amyloid
plaques were manually counted by an observer blinded
to genotype. The images of each hippocampus were out-
lined and quantified three times on three different days
to reduce bias and then analyzed. The numbers of amy-
loid plaques in each section were averaged and then
numbers of plaques from the four sections from differ-
ent levels of the brain were averaged to produce the
final number of amyloid plaques/section in the hippo-
campus of each animal.
Ab ELISA
The frozen hemi-brain from each transgenic animal was
weighed, then homogenized by sonication in five
volumes by weight in PBS with 1 × protease inhibitor
cocktail (Sigma Cat.P8340). A 100 μl aliquot of this PBS
brain homogenate was used for ELISA analysis. Protein
aggregates in the PBS homogenate were denatured by
the addition of 150 μl of 8.0 M guanidine-HCl to a final
concentration of 4.8 M, and mixed at room temperature
for three to four hours before storage overnight at -20°
C. The denatured samples were then further diluted
200-fold in reaction buffer (PBS containing 5% BSA,
0.03% Tween-20, and 1 × protease inhibitor cocktail
(Sigma)). Samples were finally prepared for application
to the ELISA microplate by mixing with an equal
volume of Standard Dilution Buffer provided by the
manufacturer supplemented with 1 × protease inhibitor
cocktail. Aliquots of these samples were assayed for
both Ab40 and Ab42 using commercially available sand-
wich-ELISAs according to the manufacturer’s manual
(Invitrogen).
Statistical analysis of the ELISA data
We compared the differences among the means of Ab40
and 42 levels among the same age groups and the distri-
bution of the levels across all ages. The comparison in
the same age group between two different genotypes
(GFAP-Cre positive or negative) was carried out using
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Excel with the two-tail Student t-test with both equal
and unequal variance. The Ab levels within each age
group were graphed in Excel and linear regression lines
were added. Excel Analysis ToolPak add-in was used for
regression analysis. IBM SPSS Statistics 19 [(trial ver-
sion), Somers, NY, USA] was used to test the signifi-
cance between the regression curves by genotypes. A P-
value of < 0.05 was considered statistically significant.
Results
A strain of GFAP-Cre mice that expresses Cre early in
neurogenesis was used to cross to the homozygous mice
with LRP1 loxp sites with the expectation of complete
recombination of flox’ed genes in neurons as well as glia
[27]. The GFAP-Cre mice that were used for this study
from the Jackson Laboratory were maintained in the FVB
strain. To make them compatible with our strains of mice,
we back-crossed them to C57BL/6J mice for four genera-
tions before crossing to LRP1 lox/lox mice, and then we
continued to cross them to C57BL/6J congenic APPswe/
PS1dE9 mice (line 85). Mice that were transgenic for
APPswe/PS1dE9 and LRP1 loxp/loxp were mated to mice
that were transgenic for GFAP-Cre and LRP1 loxp/loxp,
or mice that were transgenic for all three alleles (APPswe/
PS1dE9, GFAP-Cre and LRP1 loxp/loxp) were mated to
mice only transgenic for LRP1 loxp/loxp. A total of 54
breeding cages were set up over the course of the study to
generate the mice we ultimately examined. More than 20
of these cages failed to generate any offspring, 5 cages gen-
erated a few offspring, but the mothers failed to care for
the litters and none of the offspring lived to weaning age
(four weeks old). Of the animals of the desired genotype
(APPswe/PS1dE9/LRP1loxp/loxp/GFAP-Cre) that were
produced, almost half died suddenly in the first nine
months of life (see Additional file 1 Table S1).
Because of the reduced viability of the mice of the
desired genotype and the poor mothering of the C57BL/
6J females, we began a foster breeding program. FVB/NJ
females, (which are very good mothers), were used to
foster all newborn offspring in an effort to increase the
frequency of animals that survive to weaning. This fos-
ter-mothering program was successful in producing a
greater number of animals of the desired genotype that
survived to weaning. Surprisingly, the survival rate of
the offspring that were foster-mothered was also much
improved. A total of 167 offspring were produced in the
foster-mothering program of which only 7 died before
nine months of age and only 1 of these 7 was triple
transgenic genotype (see Additional file 1 Table S1).
Overall, the distribution of the mice with all four of the
genotypes was much closer to Mendelian distribution
(25% of each genotype expected). At present, we have
no explanation for this observation, but it appears that
the foster-mothering that improved survival to weaning
age transferred to improved resistance to the underlying
problem that caused the sudden early death after wean-
ing. Ultimately most of the mice that were studied in
this report were generated by foster-mothering.
GFAP-Cre expression in LRP1 lox/lox mice lowers LRP1
levels in hippocampus
Using the breeding scheme described above, we pro-
duced mice transgenic for GFAP-Cre, APPswe/PS1dE9,
and homozygous for the flox’ed LRP1 alleles. All mice
described in this work were homozygous for the
LRP1lox allele. No obvious developmental abnormalities
were observed in the brains of mice that were transgenic
for GFAP-Cre whether or not they were also transgenic
for the additional APPswe/PS1dE9 transgenes (not
shown). Immunoblots of hemi-brain homogenates
demonstrated that LRP1 levels were reduced by approxi-
mately 50% in mice that were transgenic for APPswe/
PS1dE9 and GFAP-Cre as compared to mice that were
transgenic only for APPswe/PS1dE9 (Figure 1).
In immunohistochemical stains of hippocampus of
mice that were double transgenic for APPswe/PS1dE9
and GFAP-Cre in the LRP1lox/lox background, we
observed very little staining for LRP1 in hippocampal
neurons in the CA fields and dentate gyrus (DG) (Figure
2; Additional file 2 Figure S1). In contrast, in APPswe/
PS1dE9/LRP1lox/lox mice we observed strong immu-
noreactivity for LRP1 in these regions (Figure 2). This
pattern of reactivity matches what would be expected
based on the levels of mRNA in these structures (Addi-
tional file 3 Figure S2). In the cortex of mice of the
same genotype, we observed that most neurons, identi-
fied by NeuN staining, remained positive for LRP1
immunoreactivity, albeit at what appeared to be slightly
lower levels, indicating that the recombination of the
flox’ed LRP1 allele was less complete in cortical neurons
(Figure 3). Thus, although the level of recombination in
the cortex was less than reported for other flox’ed alleles
[27], the level of recombination in the hippocampus was
much more robust and thus we focused our analysis on
amyloid deposition within the hippocampus.
Based on previous studies, we expected that LRP1 would
be expressed at some level in astrocytes, particularly
activated astrocytes [2-4]. No LRP1 immunoreactivity
could be detected in resting astrocytes of any genotype
(Additional file 4 Figure S3). In the hippocampus of
nine-month-old GFAP-Cre/APPswe/PS1dE9/LRP1lox/
lox mice, we observed that amyloid deposits still formed
at a relatively high frequency (see below) and around
these deposits we observed activated astrocytes. How-
ever, we failed to detect LRP1 in activated astrocytes
surrounding these plaques (Figure 4). Within these
deposits we observed LRP1 immunoreactivity that was
reminiscent of neuritic profiles (Figure 4). These LRP1
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immunoreactive neuritic profiles were mostly absent
within the molecular layer of the hippocampus of
APPswe/PS1dE9/LRP1lox/lox mice that were positive
for GFAP-Cre.
Collectively, these data indicate that the levels of LRP1 are
inherently low in astrocytes, including activated astrocytes,
and that expression of Cre via the GFAP promoter pro-
duces efficient recombination of the LRP1 gene in neurons
Figure 1 The level of LRP1 is significantly lower in the mice expressing GFAP-Cre with LRP1 lox/lox. Nine APPswe/PS1dE9 × GFAP-Cre ×
LRP1 lox/lox mice with different genotypes were used to determine the levels of LRP1. The SDS-soluble fractions of whole brain lysates
(homogenized in PBS) containing an equal amount of total protein (50 μg) was loaded in each lane. Antibody a377 to LRP1 (1:1,000, a gift from
Dr. Herz, University of Texas Southwestern Medical Center) was used to detect LRP1 level. The 85 kDa band is the endoproteolytically cleaved
mature LRP1. Mouse SOD1 (14 kD bands) was used as endogenous loading control. The ratio of band intensity of LRP1 to SOD1 was quantified,
standardized and plotted below. The standard deviations of the measurements are shown by error bars.
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of the hippocampus. We presume that any expression of
LRP1 in astrocytes was also reduced in LRP1lox/lox mice
that were transgenic for GFAP-Cre but the absence of
detectable staining in the absence of GFAP-Cre makes it
impossible to confirm this assumption.
Hippocampal deposition of Ab is not altered by reduction
in LRP1 levels
In the hippocampus of nine-month-old APPswe/
PS1dE9/LRP1lox/lox mice, we observed no obvious dif-
ference in the number of Ab immunoreactive deposits
Figure 2 LRP1 levels are reduced in hippocampal neurons of LRP1lox/lox mice that are transgenic for GFAP-Cre. Eight-month-old
APPswe/PS1dE9 × GFAP-Cre × LRP1 lox/lox littermates were used for immunostaining. All mice were homozygous for LRP1loxp alleles and
positive for APPswe/PS1dE9 transgenes. The presence or absence of GFAP-Cre is noted above the images. LRP1 a377 antibody (1:1,000, red) was
used to stain LRP1; NeuN (1:1,000, green) was used to stain neurons; Dapi in the mounting reagent was used to display nuclei. Confocal
microscope images showed most of the neurons in CA fields (A) and the dentate gyrus (C and E) of APPswe/PS1dE9 × LRP1lox/lox × GFAP-Cre
mice do not exhibit LRP1 immunoreactivity. Control mice lacking the GFAP-Cre transgene showed intense staining of LRP1 in hippocampal
neurons (B, D, and F). Three to four pairs of mice per genotype were used for immunostaining and four to five sections per animal were
analyzed.
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in mice that were positive for GFAP-Cre as compared to
mice lacking GFAP-Cre (Figure 5). With the lack of an
obvious difference in amyloid plaque burden in
APPswe/PS1dE9 mice lacking LRP1 expression in the
hippocampus, we sought to carefully quantify plaque
numbers in the hippocampus of multiple sections at
multiple levels. Tissue sections were stained with Thio-
flavin S as a means of detecting amyloid deposits and
then the hippocampus was outlined and the number of
deposits counted (see Additional file 5 Figure S4). The
number of deposits in the hippocampus of APPswe/
PS1dE9/LRP1loxp/loxp mice (n = 13) were similar to
APPswe/PS1dE9/LRP1 loxp/loxp/GFAP-Cre mice (n =
12), meaning that significantly reducing LRP1 expression
in the hippocampus had no obvious effect on the num-
ber or distribution of amyloid deposits in this structure.
Female mice of all genotypes showed slightly higher
levels of amyloid deposits as compared to males (Figure
5). We assessed whether loss of LRP1 altered any of the
morphological features of the plaque such as density of
neuritic structures, finding no obvious difference by sil-
ver staining (Additional file 6 Figure S5).
Total Ab levels do not change when LRP1 levels are
reduced
Sandwich ELISAs were used to measure the total
amount of Ab40 and Ab42 in the brains of these mice
as another means to assess amyloid burden. To comple-
tely solubilize different forms of the peptides, aggregated
or otherwise, homogenates were incubated for several
hours in guanidine-HCl before being diluted in buffer
for ELISA. Consistent with results from the amyloid pla-
que counting, ELISA measurements confirmed that the
levels of Ab40 and 42 in APPswe/PS1dE9 mice with
Figure 3 LRP1 immunostaining of cortical neurons in GFAP-Cre × LRP1lox/lox mice. Images from the same sets of mice described in the
legend to Figure 2 were captured to show cortical levels of LRP1. LRP1 a377 antibody (1:1,000, red) was used to stain LRP1; NeuN (1:1,000,
green) was used to stain neurons; Dapi in the mounting reagent was used to display nuclei. There was no obvious difference between mice
transgenic for GFAP-Cre and those lacking GFAP-Cre.
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Figure 4 LRP1 is below the level of detection in astrocytes . The same sets of mice described in the legend to Figure 2 were
immunostained. LRP1 a377 antibody (1:1,000, red) was used for LRP1 staining and antibody to GFAP (1:1,000, green) was used to mark
astrocytes. Reactive astrocytes could be seen around amyloid plaques in APPswe/PS1dE9 × LRP1lox/lox (right column) but these cells did not
show detectable levels of LRP1. Immunoreactivity to LRP1 was evident within the plaque as neuritic profiles. LRP1 immunostaining in these
neuritic structures was diminished in most hippocampal amyloid plaques of APPswe/PS1dE9 × LRP1lox/lox × GFAP-Cre mice (left column).
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reduced levels of LRP1 were no different from that of
APPswe/PS1dE9 mice with normal levels of LRP1
(Table 1 and Figure 6). Further, a regression analysis to
plot Ab levels at different ages showed that the rate of
Ab accumulation did not change by the reduction of
LRP1 levels (Additional file 7 Figure S6).
Discussion
In the present study, we have used genetic manipulation
to reduce the expression levels of LRP1 in the hippo-
campus of mice that co-express mutant APP and
mutant PS1. We demonstrate that lowering the levels of
LRP1 by approximately 50% throughout the brain and
Figure 5 Hippocampal amyloid plaque numbers do not change when LRP1 is reduced. (A and B) Representative examples of
immunohistochemical stains with 6E10 antibody (1:1,000, Covance) for Ab in APPswe/PS1dE9/LRP1lox/lox mice that were either positive or
negative for GFAP-Cre. (C) To quantify amyloid deposits, we stained sections with Thioflavin-S, which produces a sharper distinction between
tissue and amyloid plaques (see Additional file 5 Figure S4 for an example) and captured images. The hippocampus was outlined and then the
number of amyloid plaques inside the hippocampus was counted manually. A dot plot of amyloid plaque numbers in mice that were Cre+ is
compared to the numbers in mice that were Cre-. Animals that were used as breeders are noted. No significant differences between genotypes
either Cre+ (n = 12) vs. Cre- (n = 13) groups (P = 0.75) or between breeders (n = 10) vs. non-breeders (n = 15) (P = 0.69) was noted.
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possibly by a much greater degree in hippocampus had
no significant impact on the rate, severity or character
of amyloid deposition. We found no evidence of a pro-
portional change in hippocampal amyloid burden by
reducing LRP1 expression in CA and DG neurons with
no obvious morphological change in the appearance of
the plaques that formed.
To reduce LRP1 levels in the brains of APPswe/
PS1dE9 mice, we employed mice that express Cre
recombinase under the transcriptional regulation of the
GFAP promoter and mice in which the LRP1 allele has
been modified by introduction of lox p sites. The
GFAP-Cre mice have previously been used in several
studies and these investigations have previously demon-
strated that Cre is expressed early in neurogenesis such
that targeted genes may recombine in both neurons and
glia [26,27]. In our cross of the GFAP-Cre mice with
LRP1lox/lox mice, we observed efficient targeting of
LRP1 expression in the hippocampal neurons. However,
cortical neurons continued to show demonstrable LRP1
immunoreactivity. We note, that in the hippocampus, a
subset of neurons in the molecular layer continued to
express LRP1 in GFAP-Cre/loxp/loxp mice; however,
the levels in CA and DG neurons were dramatically
reduced. The levels of LRP1 in astrocytes appeared to
be inherently low and we could not confirm whether or
not expression of LRP1 was reduced further in LRP1lox/
lox mice harboring the GFAP-Cre.
We observed no obvious developmental abnormality
or reductions in the numbers of CA and DG neurons in
mice transgenic for GFAP-Cre and LRP1 loxp/loxp, or
mice of this genotype that were also transgenic for
APPswe/PS1dE9. However, as noted in Results, we
encountered significant difficulty in breeding these ani-
mals and noted a high degree of lethality early in the
process. For reasons that remain unknown, these issues
were overcome using a strategy of foster mothering with
FVB/NJ females. The APPswe/PS1dE9 mice and the
LRP1 loxp mice were both congenic in the C57BL/6J
background and we bred the GFAP-Cre into C57BL/6J
mice for four generations before beginning the crosses
to produce experimental animals. In our hands, mice of
the C57BL/6J strain are poorer mothers than commonly
used hybrid strains or the inbred FVB/NJ strain. As we
expected, foster mothering solved issues we had with
poor mothering by C57BL/6J females. Unexpectedly, off-
spring that were foster-mothered by FVB/NJ females
survived much better than mice of the same genotype
mothered by C57BL/6J females. We presently have no
explanation for this outcome. We note that in a pre-
vious effort to cross congenic C57BL/6J APPswe/
PS1dE9 mice to congenic C57BL/6J RAP knockout mice
we observed a high level of lethality in mice that were
transgenic for APPswe/PS1dE9 and homozygous knock-
out for RAP [22]. RAP is a direct ER chaperone for
LRP1 and loss of RAP lowers the level of mature LRP1
that reaches the cell surface [37]. Notably, others
observed no issues in crosses of the PDAPP mouse
model to RAP knockout mice [23], so we concluded
that the lethality we observed our earlier work was due
to some interaction between mutant PS1 and RAP. Our
experience in the mating of the LRP1 loxp mice to
APPswe/PS1dE9 mice leads us to believe that there may
be some more complex interaction between PS1dE9 and
RAP/LRP1 that reduces viability. This current study
defines the source of this defect to the nervous system
because LRP1 is only reduced in the brain by the
expression of GFAP-Cre. Although likely to be unrelated
to AD, further examination of the basis of this lethality
may reveal functions of APPswe or PS1dE9 that impact
CNS function.
Because the reduction in neuronal LRP1 was greatest
in the hippocampus, we focused our pathologic analyses
on the hippocampus, finding no significant change in
the severity of amyloid deposition when LRP1 levels
were reduced in the APPswe/PS1dE9 mice. The data
shown in Figure 5C document the variability in the
number of amyloid deposits in hippocampus between
Table 1 The levels of Ab in the brains of mice of each genotype and age
Age (month) Cre N Ab40 (pg/mg brain) Ab42 (pg/mg brain) ratio 40/42
Average STDEV.P P-value Average STDEV.P P-value
8 - 3 1,257 1,022 0.40 271 193 0.45 4.6
+ 3 481 315 142 75 3.4
9 - 17 2,024 1,192 0.90 399 192 0.71 5.1
+ 12 2,074 746 421 116 4.9
15 - 4 4,235 946 0.65 1,015 104 0.74 4.2
+ 4 4,582 823 972 188 4.7
16 to 18 - 4 4,445 1,135 0.74 971 181 0.79 4.6
+ 5 4,830 1,777 1,020 289 4.7
There was no difference in the levels of Ab40 and 42 in the brains of mouse expressing APPswe/PS1dE9 gene in the LRP1 lox/lox homozygous background in
the absence or presence of the GFAP-Cre transgene in any given age group.
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mice that are positive and negative for Cre recombinase.
In both groups, the number of animals that were below
and above the mean (horizontal line) was similar. Nota-
bly, if the number of deposits had been reduced by just
30% (with the same level of variance), then we would
have been able to have reached statistical significance (P
= 0.05) with just 10 animals in each group (our n’s were
12 vs. 13). Based on quantification of immunoblots from
Figure 6 Ab ELISA assay of whole brain homogenates show no differences in Ab levels by genotype. Ab levels in 8-, 9-, 15- and 16 to
18-month-old with normal LRP1 levels (APPswe/PS1dE9(+)/LRP1lox/lox) were compared to those with lower LRP1 levels (GFAP-Cre +). There was
no difference in Ab levels by genotype by age (p values range 0.40 to 0.90 based on Student’s t-test). ELISA data used to generate the graph are
shown in Table 1, which includes information on the number of animals used at each age.
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hemi-brains, we conservatively estimate that the mini-
mum reduction in LRP1 levels would be in the range of
50%. By power calculation, we should have been pow-
ered to observe a 30% decrease in amyloid plaque num-
bers and thus we conclude that reducing LRP1 levels
does not produce a proportional decrease in amyloid
plaque numbers. Consistent with our findings, Zerbinatti
and colleagues reported that increasing the levels of
LRP1, via expression of a recombinant mini-receptor,
did not produce a proportional increase in amyloid bur-
den [25]. However, this study did note small increases
of levels of both soluble and insoluble Ab in the cortex
with a more selective increase in soluble Ab in the hip-
pocampus of older mice with high amyloid burden. Our
measures of total Ab did not find evidence that reducing
LRP1 levels produced a change in the accumulated
levels of Ab. Zerbinatti and colleagues also noted the
appearance of Ab42 dimers after extraction in buffers
containing 0.1 M carbonate. We have not been able to
reliably detect dimeric Ab in our APPswe/PS1dE9 mice
at any age and thus we cannot comment as to whether
reducing LRP1 reduces the levels of these dimers.
Interpreting the outcome of this work is not as
straightforward as one would like because the LRP1
levels were not reduced to zero. One issue is that we do
not know how much LRP1 must be expressed to sustain
amyloidogenesis or whether we should expect changes
in amyloid formation in proportion to changes in LRP1
levels. Additionally, the source of the Ab peptides that
produce deposits may be neurons that project axons
into the hippocampus as well as local neurons. Within
the hippocampus, we observed a near elimination of
LRP1 immunoreactivity of neurons of the CA fields.
However, the hippocampus receives axonal projections
from the entorhinal cortex making it possible that an
activity of LRP1 in cortical neuronal projections masked
any effect of local reductions in LRP1 levels in hippo-
campus. Ultimately, the most conservative interpretation
is that significant suppression of LRP1 activity in local
hippocampal neurons does not produce a proportional
decrease in amyloid plaque numbers this structure.
Apart from the potential effects of LRP1 reductions on
amyloid plaque levels, we had anticipated that we might
see some change in neuritic pathology. Nearly all amy-
loid plaques in APPswe/PS1dE9 mice contain apolipo-
protein E (ApoE) [31] and ApoE is known to be a
ligand for LRP1 that modulates neurite outgrowth [38].
Thus, we had thought it possible that reducing LRP1
locally in the hippocampus could have reduced neuritic
pathology around amyloid plaques. Notably, in APPswe/
PS1dE9/LRP1lox/lox mice that were positive for GFAP-
Cre we observed large neuritic plaques in which the
neurites were depleted of LRP1 immunoreactivity.
Conclusions
This study used genetic tools to reduce LRP1 levels in
the brains of mice that co-express APPswe/PS1dE9 and
develop amyloid pathology, producing a model in which
LRP1 levels in most hippocampal neurons were lowered
to below the level of detection by immunohistochemis-
try. In the hippocampus of mice with reduced LRP1
levels, we observed no obvious change in the rate of
deposition, severity, or character of amyloid deposits.
Obviously, this study does not provide any insight into
what LRP1 expressed in non-neural cell types, such as
endothelial cells, other organs may do in regard to mod-
ulating amyloid deposition. It is also very possible that
homologues of LRP1 may have compensated for any
effect of reducing the levels of LRP1. However, at mini-
mum, our study indicates that reducing the levels of
LRP1 does not produce proportional reductions in amy-
loid plaque numbers in the hippocampus of the
APPswe/PS1dE9 model. Thus, this genetic test does not
produce supportive evidence for the notion that modu-
lating LRP1 function in neurons or glial could be benefi-
cial in modulating amyloidosis. Whether this outcome is
unique to the APPswe/PS1dE9 model is of course an
issue in assessing the potential importance of this path-
way in human disease.
Additional material
Additional file 1: Genotype distribution of the transgenic mice used
in this study. In total, 325 transgenic mice with LRP1 lox/lox
background were generated. The mice listed in the table are those that
reached weaning age and survived to at least 1.5 months of age. The
actual and expected percentages of mice of each genotype are listed.
The predicated frequency rate is based on Mendelian distribution. As is
typical for APPswe/PS1dE9 mice that are found dead, there were no
obvious birth defects to account for the early lethality (Table S1).
Additional file 2: Low power image of LRP1 immunostaining in
hippocampus of APPswe/PS1dE9/LRP1 lox/lox mice that are
positive or negative for GFAP-Cre. Free-floating frozen sections were
immunostained as described in Methods of the main text. The images
shown are representative of what was observed in at least three animals
of each genotype (Figure S1).
Additional file 3: Low power image captured from the Allen Brain
Atlas. The image shown here was captured from the website for the
Allen Brain Atlas for the adult mouse brain. The gene name searched for
was LRP1. The view shown displays false color for expression levels of a
sagittal view (Figure S2).
Additional file 4: Resting astrocytes are not immunoreactive to
LRP1 antibodies. The images shown are high power images of
hippocampus from APPswe/PS1dE9/LRP1 lox/lox mice that were either
positive or negative for GFAP-Cre. We observed no obvious reactivity in
cells showing a morphology identified by GFAP staining and there was
no indication of significant co-localization of GFAP and LRP1
immunoreactivity. The images shown are representative of what was
observed in at least three animals of each genotype (Figure S3).
Additional file 5: Thioflavin-S staining of hippocampal sections. The
numbers of amyloid plaques in the hippocampus as identified by
Thioflavin-S staining section were manually by outlining the border of
the hippocampus on the image and then counting the number of
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plaques in hippocampus. These images show representative examples of
animals of both genotypes (Figure S4).
Additional file 6: The morphology of hippocampal amyloid deposits
is unchanged by the lack of LRP1. Silver stains of 30 μm sections from
APPswe/PS1dE9 × LRP1 lox/lox mice that were either positive or
negative for GFAP-Cre. White arrows mark neurites and the white arrow
heads mark to the core of the plaques (Figure S5).
Additional file 7: Regression analysis of Ab levels in mice of each
genotype by age. No difference in the rate of Ab accumulation was
evident. The regression curve of the slopes between two groups of
animals is not significant for Ab40 (P = 0.409) or Ab42 (P = 0.864) (Figure
S6).
Abbreviations
ApoE: apolipoprotien E; APP: amyloid precursor protein; APPswe/PS1dE9: a
tandem integration of transgenes encoding amyloid precursor protein with
the Swedish mutation and presenilin 1 gene with exon 9 deletion; BCA:
bicinchoninic acid assay: a biochemical assay for protein concentration; CA:
cornu ammonis in hippocampus; Cre-lox: Cre recombinase-Lox P site system,
a genetic tool to control site specific recombination events in genomic
DNA; DG: dentate gyrus in hippocampus; ELISA: enzyme-linked
immunosorbent assay; GFAP-Cre: transgenic mice with Cre recombinase
driven by glial fibrillary acidic protein (GFAP) promoter; LRP1: low-density
lipoprotein receptor-related protein.
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